interactions, these recommendations do not tailor dosing to individual patients (Ageno et al., 2012) .
Candidate gene studies
The recognition of genetic regulation of warfarin response has stimulated efforts aimed at quantifying this influence. The bulk of the evidence supports the influence of single nucleotide polymorphisms (SNPS) in two genes; Cytochrome P450 2C9 (CYP2C9; codes for the main enzyme involved in warfarin metabolism) and Vitamin K epoxide reductase complex1 (VKORC1; encodes the vitamin K-epoxide reductase protein, the target enzyme of warfarin). The influence of SNPs in CYP2C9 and VKORC1 on warfarin dose has been extensively assessed and reviewed (Wadelius et al., 2007 (Wadelius et al., , 2009 Limdi and Veenstra, 2008; Cavallari and Limdi, 2009; Klein et al., 2009) . This evidence provided the basis for the recent warfarin package insert update by the United States Food and Drug Administration (FDA).
Moreover clinical algorithms that can enable dose prediction incorporating patient-specific genetic and clinical information have been developed and are freely available. Gage et al. (2008) have developed a dosing algorithm based on clinical and demographic factors (body surface area, age, target INR, amiodarone use, smoker status, race, current thrombosis) along with CYP2C9 (*2, *3, *5, and *6), VKORC1 (−1639/3673G>A), GGCX (rs11676382), and CYP4F2 (V433M) polymorphisms. The algorithm is freely available at www. warfarindosing.org and allows calculation of warfarin dose based on clinical and demographic factors alone (if genotype is not available). Incorporation of novel and potentially important genetic variants (such Despite its wide use over six decades, warfarin therapy remains challenging due its narrow therapeutic index. The multitude of factors interacting with warfarin makes it difficult to maintain anticoagulation within the target International Normalized Ratio (INR) range (Ageno et al., 2012) . Even within this range the dose requirements vary as much as 20-fold between patients.
Deviations in INR control with frequent over and under-anticoagulation are common (Chiquette et al., 1998; Chamberlain et al., 2001; Ansell et al., 2007) , are associated with poor outcomes with underanticoagulation (increasing the risk of thrombosis) and over-anticoagulation (increasing the risk of serious or fatal hemorrhage), demanding that anticoagulation control be tightly regulated (Hylek and Singer, 1994; Hylek et al., 1996 Hylek et al., , 2000 Hylek, 2003; Wittkowsky, 2004; Wittkowsky and Devine, 2004; Hylek and Rose, 2009 ). These adverse outcomes have relegated warfarin to the "top 10 drugs" for adverse drugrelated hospitalizations in the US (Budnitz et al., 2007 (Budnitz et al., , 2011 . Between 2007 and 2009 warfarin accounted for 33% of drug-related hospitalizations for adverse events in the US (Budnitz et al., 2011) . The risk for hemorrhage is particularly elevated when the INR exceeds four, as well as during the initial months of therapy. Therefore it is critical to achieve a safe and effective level of anticoagulation for patients starting warfarin.
Current guidelines for initiation of therapy provided by the American College of Chest Physicians (ACCP) allow flexibility in selecting a starting dose of warfarin, suggesting 5-10 mg. Although the ACCP guidelines recommend lower (2.5-5 mg) doses recognizing the influence of age, comorbidities, nutritional status, and drug as CYP2C9*8) can further improve dosing prediction in African American patients Cavallari and Perera, 2012) .
As demonstrated by multiple studies, including the work of the International Warfarin pharmacogenetics Consortium (IWPC), dosing based on clinical/demographic factors alone improves prediction of stable therapeutic dose of warfarin (compared to the one-size-fits-all 5 mg/ day dose), specifically in patients that need ≥7 mg/day or ≤3 mg/day. Furthermore inclusion of CYP2C9 and VKORC1 provide a substantial gain in improvement of dose prediction in 46% of patients (Klein et al., 2009 ). The www.warfarindosing.org also allows the user to compute the estimated dose requirements based on the IWPC algorithm.
Both pharmacogenetic algorithms Klein et al., 2009) (Finkelman et al., 2011) .
The Clinical Pharmacogenetics Implementation Consortium (CPIC) of the National Institutes of Health Pharmacogenomics Research Network has developed guidelines to assist clinicians in the interpretation and use of CYP2C9 and VKORC1 genotype data for estimating therapeutic warfarin dose to achieve an INR of 2-3, should genotype results be available to the clinician. These guidelines are published and
Pressing Challenges

Will pharmacogenetic/genomic interventions have an impact on clinically meaningful outcomes?
Although extensive research efforts have identified several genetic markers strongly associated with outcomes of interest and hailed them as promising tools, these proclamations are based mainly on associations rather than their evaluation as predictors. Moreover such evaluations must be based on clinically relevant hard-endpoints such as anticoagulation control, hemorrhage and health-care utilization and costs (Limdi and Veenstra, 2010) . At the crux of this debate are three questions:
a) Can a genetic risk factor (genetic marker) associated with an adverse (or beneficial) outcome be a clinically useful predictor of that outcome? (clinical validity)
• CYP2C9 and VKORC1 genotypes are clinically useful predictors of warfarin dose in clinical trials (Anderson et al., 2007 (Anderson et al., , 2012 . b) Can incorporation of the genetic factor predict risk of the outcome more accurately than existing clinical models? (Clinical utility)
• Incorporation of CYP2C9 and VKORC1 genotypes provided superior warfarin dose prediction compared with the clinical algorithm (or the fixed 5-mg dose algorithm; Klein et al., 2009; Anderson et al., 2007 Anderson et al., , 2012 
genome-wide assoCiation studies
To identify other genes/SNPs that can explain variability in warfarin dose two genome-wide association studies (GWAS) have been conducted. Among patients of European descent these studies have confirmed the influence of VKORC1, CYP2C9, and identified CYP4F2 as the main genes associated with dose (Cooper et al., 2008; Takeuchi et al., 2009; Cha et al., 2010) . The genome-wide significance of the latter association remains to be confirmed. These studies suggest that identification of common variants in other genes exhibiting influence of magnitude similar to that of CYP2C9 and VKORC1 is unlikely, at least in Whites. As these known variants in candidate genes account for a smaller percent of the variability in warfarin dose among Blacks, the IWPC is leading a GWA analysis in Blacks. Preliminary results of the ongoing GWAs meta-analysis were presented at the 2011 American Heart Association meeting (Perera et al., 2011) . A parallel effort is planned to conduct a GWAs meta-analysis for multiple population groups (Whites, Asians, African American, Japanese, and Middle-Eastern).
Despite these efforts a large portion (40% among White and 60% among Blacks) of the variability in warfarin dose remains unexplained. Perhaps emerging genotyping technologies such as exome sequencing or whole genome sequencing will reveal important clues that can explain the missing heritability. In addition to interrogating genetic variation ongoing and future studies must assess in detail environmental (diet, smoking alcohol, etc.) and lifestyle (compliance, exercise, etc.) factors with similar rigor. It is very likely that this along with gene-environment interactions holds the key to explaining the majority of the variability in response.
One group that remains unrepresented is the Hispanic/Spanish population. This is of great importance in the US as people of Hispanic descent accounted for more than half the growth in the population between 2000 and 2010 and account for 16.3% of the US population (surpassing Blacks who account for 12.3%; U.S.Census Bureau, 2010). effectiveness of utilizing pharmacogenetics in a real-world setting (Anderson et al., 2012 Johnson, 2012; Pradaxa, 2012) , warfarin remains the most widely used oral anticoagulant (25 million users) (Schirmer et al., 2010; Altman and Vidal, 2011; Cabral et al., 2011; Wittkowsky, 2011; Tzeis and Andrikopoulos, 2012) . The Practice INNovation And CLinical Excellence (PINNACLE) registry focusing on patients with atrial fibrillation (AF) reports among patients who received oral anticoagulation, 87.4% were treated with warfarin while just 12.6% were prescribed one of the two new oral anticoagulants (Cardiology, 2012) . The oral anticoagulant market is expected to exceed $ 9 billion by 2014 (Melnikova, 2009) , driven by demographics of the aging population and increased incidence of cardiovascular disease, and the uptake of newly approved agents. Although the market share of DBG (and the newer agents) is expected to increase, its uptake is hindered by lack of monitoring, reversibility, and expense. Almost 2 years after approval of DBG, warfarin remains the most widely used oral anticoagulant.
Despite the approval of four CYP2C9/ VKORC1 rapid throughput genotyping platforms by the U.S. FDA over the last decade clinical implementation of genotype-guided dosing is lagging. Although genotypeguided therapy improves dose prediction is recognized, evidence that such an intervention will improve anticoagulation control, reduce risk of adverse events and health-care costs is limited. Results of ongoing clinical trials are expected to address these issues and will perhaps provide the much needed impetus to reevaluate reimbursement for genetic testing and for wider implementation.
The challenges unique to pharmacogenomic efforts have created an intangible benefit for science and humanity. Of note, most genetic/genomic investigations have identified genes with small effect sizes. To enable these discoveries investigators stepping outside the conventional paradigm of lab-based investigative efforts formed consortia to build collaborations across laboratories, departments, institutions, countries, and continents. Investigators within these consortia sharing a common goal, pooled unpublished data, working with complete strangers, while maintaining enviable focus NCT01305148) is a randomized blinded interventional trial where 4300 patients (age > 65 years) are to be randomized to warfarin dosing based on the GenoSTAT test plus clinical factors, or clinical factors alone, using the warfarindosing.org website. The primary aim is to determine if genotype-guided therapy reduces the incidence of warfarin-related clinical events, including major hemorrhage and thromboembolic events at 30 days and in fewer hospitalizations and/or deaths compared to clinically guided therapy at 90 days compared to clinically guided therapy.
Additional information on the trials below and others can be found at www. clinicaltrials.gov. These trials will provide a robust data for efficacy/effectiveness and cost effectiveness analysis and will provide the foundation for policy development. Although detractors claim pharmacogenetics/genomics in general has not yielded information to justify the investment of effort and funds, progress in the genomics/genetics arena has been maintained a rapid pace compared to other fields in medicine. For warfarin, the first report identifying the CYP2C9 *2 polymorphism was published in 1994. With the discovery of VKORC1 in 2004 the field burgeoned with investigations in multiple populations across the world documenting the effect of CYP2C9 and VKORC1 on warfarin dose, anticoagulation control, and risk of hemorrhage. Twenty years from the report identifying the CYP2C9 *2 (10 years following the identification of VKORC1), the results of the first double-blinded randomized clinical trial (COAG trial) testing genotype-guided dosing intervention are expected to be available. 3. Although the uptake of newly available oral anticoagulants is slow, a frequently raised question is "Will warfarin or warfarin pharmacogenetics matter in the coming years?" The introduction of Dabigatran (DBG; October 2010), Rivaroxaban (2011) , and Apixaban (awaiting approval) is changing the landscape of anticoagulation therapy (Melnikova, 2009; Weitz et al., 2012) . Although the use of DBG is increasing (0.6 million users in the US; and relentless effort to advance science. Among the consortia, the IWPC has successfully brought together >100 investigators from >25 institutions across >10 countries providing valuable contributions (Klein et al., 2009; Perera et al., 2011) to the pharmacogenetic literature and much needed insight to inform the design of ongoing clinical trials in five short years. One has to but conduct a PubMed search for GWAS for their favorite disease/phenotype and scroll through the authors and contributors list to understand the magnitude of such efforts, the network of collaborators created and progress made. These collaborations will continue (beyond the single publication) to advance science and enable discoveries beyond what can be gaged solely by investments; past, current, and future.
